Location Directory

Clinical trials in Durham, North Carolina

This page shows live ClinicalTrials.gov search results for Durham, North Carolina, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1196

Shown on this page

Current sort

Institutions in Durham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Duke University Medical Center

Live official records

Open in full search

Conditions: Ventricular Fibrillation, Ventricular Tachycardia, Low Cardiac Output
Interventions: EMBLEM S-ICD System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 1,173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more

Conditions: Sickle Cell Disease
Interventions: Safety and efficacy assessments; Other
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: 2 Years to 53 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2038
U.S. locations: 15
States / cities: Birmingham, Alabama • Oakland, California • Atlanta, Georgia + 12 more

Conditions: Quality of Life
Interventions: Not listed
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 5 Years and older
Enrollment: 754 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 27 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 87
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 77 more

Conditions: Covid19
Interventions: Apixaban 2.5 MG, Placebo; Drug
Lead sponsor: Thomas L. Ortel; Other
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 121
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more

Conditions: Ventricular Septal Defects
Interventions: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 48
States / cities: Phoenix, Arizona • Los Angeles, California • Madera, California + 40 more

Conditions: Acute Myeloid Leukemia
Interventions: Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 36
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 28 more

Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Interventions: Ad26.COV2.S, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 44,325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 117
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: ALS-008176, Placebo; Drug
Lead sponsor: Alios Biopharma Inc.; Industry
Eligibility: Up to 12 Months
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more

Conditions: Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
Interventions: HSPPC-96, bevacizumab; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 417
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more

Conditions: Hematological Malignancies
Interventions: Magrolimab, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 26
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 20 more

Conditions: Acute Myeloid Leukemia
Interventions: gilteritinib, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more

Clinical trials in Durham, North Carolina

Filter and sort this location

Institutions in Durham

Live official records

Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

A Study of ALS-008176 in Infants Hospitalized With RSV

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)